Sarbajit Mukherjee   (MD, MS)

Dr. Sarbajit Mukherjee is a board-certified medical oncologist and hematologist specializing in gastrointestinal (GI) malignancies, with a focus on gastroesophageal cancers and cancer immunotherapy. He completed his clinical fellowship in adult hematology-oncology at the University of Oklahoma, where he also earned a Master’s degree in Clinical and Translational Science. His research training at the Oklahoma Medical Research Foundation provided him with extensive laboratory experience, reinforcing his commitment to integrating translational research with patient care. A committed leader in oncology, Dr. Mukherjee has actively contributed to the American Society of Clinical Oncology (ASCO) through various roles, including as a member of the Trainee Council Working Group, Clinical Practice Guidelines Committee, and Professional Development Committee. He has also served on multiple ASCO guideline panels and is currently a panel member at the National Comprehensive Cancer Network (NCCN). Additionally, he sits on the Board of Directors of the Esophageal Cancer Action Network. Dr. Mukherjee has been recognized with numerous honors, including induction into the Alpha Omega Alpha Medical Honor Society and the Gold Humanism Honor Society. He is also a recipient of an ASCO Merit Award. His research is centered on novel clinical trials utilizing circulating tumor DNA (ctDNA) as a biomarker in GI malignancies and investigating the role of obesity in cancer-related immune dysfunction. He has led several investigator-initiated studies, including a Phase II trial funded by the National Cancer Institute (NCI), and has secured competitive grants from the NCCN and the North American Neuroendocrine Tumor Society (NANETS). His work has been featured at leading scientific meetings and published in high-impact journals such as Nature Medicine. He also serves as a peer reviewer for respected journals including Clinical Cancer Research. Dr. Mukherjee views oncology as a holistic discipline that addresses not only disease but also the emotional and psychological journey of each patient. His vision is to be a compassionate clinician, a dedicated researcher, and a thought leader in the field of gastrointestinal cancers.

Disclosure